These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10828350)

  • 21. Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.
    Barnes MJ; Estlin EJ; Taylor GA; Aherne GW; Hardcastle A; McGuire JJ; Calvete JA; Lunec J; Pearson AD; Newell DR
    Clin Cancer Res; 1999 Sep; 5(9):2548-58. PubMed ID: 10499632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of p53 status on cellular sensitivity to antifolate drugs.
    Lu X; Errington J; Curtin NJ; Lunec J; Newell DR
    Clin Cancer Res; 2001 Jul; 7(7):2114-23. PubMed ID: 11448931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites.
    ELION GB; SINGER S; HITCHINGS GH
    J Biol Chem; 1954 Jun; 208(2):477-88. PubMed ID: 13174557
    [No Abstract]   [Full Text] [Related]  

  • 24. Antifolates in clinical development.
    Takimoto CH
    Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-40-S18-51. PubMed ID: 9420020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of pemetrexed in lung cancer.
    Wang D; He J
    Curr Drug Targets; 2010 Jan; 11(1):1. PubMed ID: 20017724
    [No Abstract]   [Full Text] [Related]  

  • 26. [Pemetrexed: from preclinic to clinic].
    Lansiaux A; Lokiec F
    Bull Cancer; 2007; 94 Spec No Actualites():S134-8. PubMed ID: 17845983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow.
    Das JR; Fryar-Tita EB; Green S; Southerland WM; Bowen D
    Anticancer Res; 2007; 27(2):825-33. PubMed ID: 17465208
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pemetrexed: mRNA expression of the target genes TS, GARFT and DHFR correlates with the in vitro chemosensitivity of human solid tumors.
    Eismann U; Oberschmidt O; Ehnert M; Fleeth J; Lüdtke FE; Struck S; Schulz L; Blatter J; Lahn MM; Ma D; Niyikiza C; Paoletti P; Hanauske AR
    Int J Clin Pharmacol Ther; 2005 Dec; 43(12):567-9. PubMed ID: 16372519
    [No Abstract]   [Full Text] [Related]  

  • 29. Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines.
    Gangjee A; Vidwans A; Elzein E; McGuire JJ; Queener SF; Kisliuk RL
    J Med Chem; 2001 Jun; 44(12):1993-2003. PubMed ID: 11384244
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biochemical pharmacology of pemetrexed.
    Calvert AH
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):13-7. PubMed ID: 15655931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay.
    Britten CD; Izbicka E; Hilsenbeck S; Lawrence R; Davidson K; Cerna C; Gomez L; Rowinsky EK; Weitman S; Von Hoff DD
    Cancer Chemother Pharmacol; 1999; 44(2):105-10. PubMed ID: 10412943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interaction of pemetrexed disodium (ALIMTA, multitargeted antifolate) and irradiation in vitro.
    Bischof M; Weber KJ; Blatter J; Wannenmacher M; Latz D
    Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1381-8. PubMed ID: 11955753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical potency of methotrexate, aminopterin, talotrexin and pemetrexed in childhood leukemias.
    Norris RE; Adamson PC
    Cancer Chemother Pharmacol; 2010 May; 65(6):1125-30. PubMed ID: 19784838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of a folate transporter in HeLa cells with a low pH optimum and high affinity for pemetrexed distinct from the reduced folate carrier.
    Wang Y; Zhao R; Goldman ID
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6256-64. PubMed ID: 15448015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers.
    Izbicka E; Diaz A; Streeper R; Wick M; Campos D; Steffen R; Saunders M
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):993-9. PubMed ID: 19221750
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enzastaurin and pemetrexed exert synergistic antitumor activity in thyroid cancer cell lines in vitro.
    Oberschmidt O; Eismann U; Schulz L; Struck S; Blatter J; Lahn MM; Ma D; Hanauske AR
    Int J Clin Pharmacol Ther; 2005 Dec; 43(12):603-4. PubMed ID: 16372535
    [No Abstract]   [Full Text] [Related]  

  • 37. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514.
    Schultz RM; Patel VF; Worzalla JF; Shih C
    Anticancer Res; 1999; 19(1A):437-43. PubMed ID: 10226579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 5,10-Dideaza-5,6,7,8-tetrahydrofolic acid (DDATHF): a potent inhibitor of purine biosynthesis.
    Nutr Rev; 1990 Nov; 48(11):421-3. PubMed ID: 2080047
    [No Abstract]   [Full Text] [Related]  

  • 39. Pemetrexed: a multitargeted antifolate (ALIMTA, LY-231514).
    Jones RJ; Twelves CJ
    Expert Rev Anticancer Ther; 2002 Feb; 2(1):13-22. PubMed ID: 12113062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulation of carrier-mediated transport of folates and antifolates in methotrexate-sensitive and-resistant leukemia cells.
    Jansen G; Mauritz RM; Assaraf YG; Sprecher H; Drori S; Kathmann I; Westerhof GR; Priest DG; Bunni M; Pinedo HM; Schornagel JH; Peters GJ
    Adv Enzyme Regul; 1997; 37():59-76. PubMed ID: 9381986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.